

Management of Lower Limb Deep Venous Thrombosis in the Acute Take

Tamer Shalaby Boutrus^{1*} and Zain Alqudah²

Abstract

Patients presenting with lower limb swelling, pain, redness and warmth should be evaluated for deep venous thrombosis (DVT).

A modified Wells score (Table 1), which is a combination of clinical findings and history should be applied, if DVT felt to be likely then USS doppler exam is the next step regardless of D-Dimer blood test, while if DVT is felt to be unlikely according to modified Wells score then D-Dimer can be applied, if positive then proceed with USS doppler exam. Proximal DVT is a blood clot in the popliteal, femoral, or iliac veins, which has a high risk of embolization compared to DVT in the calf veins.

Distal DVT (blood clot below knee) should be treated if there is a high risk of embolization, while distal DVT with low risk of embolization can be monitored with serial doppler ultrasound scans as resolution of the DVT is expected.

Keywords: Deep Venous Thrombosis (DVT); Blood clot; Embolization.

Abbreviations: DVT: Deep Venous Thrombosis; VTE: Venous Thromboembolism; PE: Pulmonary Embolism; LMWH: Low Molecular Weight Heparin; MRI: Magnetic Resonance Imaging.

Introduction

Patients presenting with lower limb swelling, pain, redness and warmth should be evaluated for deep venous thrombosis (DVT) [1].

A modified Wells score (Table 1), which is a combination of clinical findings and history should be applied, if DVT felt to be likely then USS doppler exam is the next step regardless of D-Dimer blood test, while if DVT is felt to

be unlikely according to modified Wells score then D-Dimer can be applied, if positive then proceed with USS doppler exam [2].

Proximal DVT is a blood clot in the popliteal, femoral, or iliac veins, which has a high risk of embolization compared to DVT in the calf veins [3]. Early treatment as soon as a proximal DVT is expected is advisable, the rate of recurrence or progression to a fatal

¹Consultant Internal Medicine, The View Hospital, Lusail, Qatar

²Internal Medicine Specialist, The View Hospital, Lusail, Qatar

*Corresponding Author: Tamer Shalaby Boutrus, Consultant Internal Medicine, The View Hospital, Lusail, Qatar.

Received Date: 03-19-2024

Accepted Date: 04-07-2024

Published Date: 04-25-2024

Copyright© 2024 by Boutrus TS, et al. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

DVT or pulmonary embolism (PE) is high in the first three months of the initial DVT [4].

Discussion

Distal DVT (blood clot below knee) should be treated if there is a high risk of embolization, while distal DVT with low risk of embolization can be monitored with serial doppler ultrasound scans as resolution of the DVT is expected [5]. Symptomatic distal DVT is a high risk one and can potentially extend into the proximal veins in more than 30% of cases, this extension usually occurs within two weeks [6]. Treating symptomatic distal DVT is advisable as anticoagulation treatment can reduce the risk of recurrence as

well as propagation to a proximal DVT or pulmonary embolism [7]. While asymptomatic distal DVT can be monitored by surveillance as mentioned above due to low risk of recurrence or extension, however, few asymptomatic distal DVTs can have a high risk for proximal extension. High risk factors for asymptomatic distal DVT are unprovoked DVT, extensive thrombosis including multiple veins, DVT within 2 cm of the popliteal vein, provoked DVT with persistent risk factors like cancer or immobility long term, and recurrent DVT or PE. Extension commonly occurs within two weeks and beyond this period it is unlikely to occur [8].

Clinical Feature	Points
Active Cancer (treatment ongoing, within 6 months, or palliative)	1
Paralysis, paresis or recent plaster immobilization of the lower limb	1
Recently bedridden for 3 days or more or major surgery within system	1
Entire leg swollen	1
Calf swelling at least 3 cm larger than asymptomatic side	1
Pitting oedema confined to the symptomatic leg	1
Collateral superficial veins(non-varicose)	1
Previously documented DVT	1
An alternative diagnosis is at least as likely as DVT	-2
Clinical probability simplified score	
DVT likely	2 points or more
DVT unlikely	1 point or less

Table 1: Two-levels DVT wells score.

PE as well as DVT present simultaneously, high Therefore, the ideal surveillance is to perform USS doppler on popliteal and femoral veins once weekly for two weeks. Clot at or within 2 cm of the popliteal veins should be treated as DVT [9]. Treatment of proximal DVT or symptomatic or high risk asymptomatic distal DVT is indicated in patients with low risk of bleeding to reduce

recurrence, propagation, embolization, and post phlebitis syndrome [10]. Treatment of DVT should be for three months atleast, the rationale as mentioned before is the highrisk of recurrence and embolization during this period, treatment can be extended to six months or even lifelong depending on risk benefit ratio and presence of risk factors or recurrence of venous thromboembolism

(VTE). Outpatient treatment of DVT can be initiated in ambulatory clinics if the patient is hemodynamically stable with normal renal function and low risk of bleeding. While inpatient initiation of anticoagulation is advisable if both risk of bleeding, multiple comorbidities, and massive iliofemoral clot burden or DVT causing phlegmasia cerulea dolens [11].

Treatment options for DVT or high-risk distal blood clot includes, factor Xa inhibitors (Apixaban, Rivaroxaban) which are both safe and effective as monotherapy for acute DVT in outpatient setting, their advantage over Edoxaban and warfarin is the lack of necessity to initiate heparin and no monitoring required as we do with warfarin [12]. Enoxaparin is a low molecular weight heparin (LMWH) and a dose of 1 mg/Kg twice daily has been better validated than the 1.5 mg/kg dose, LMWH has shown to be more efficient in reducing the rate of VTE recurrence, major bleeding, and mortality when compared to unfractionated heparin [13]. Dabigatran is a direct thrombin inhibitor and edoxaban is factor Xa inhibitor, both agents require LMWH for 5 days at least during initiation of treatment [14]. Patients with acute DVT and absolute contraindication to anticoagulation should be referred for Inferior vena cava (IVC) filter placement to reduce DVT embolization, and when and if anticoagulation is initiated, IVC filter can be removed [15]. Although IVC

filter can reduce the risk of PE on the short term but the risk of DVT, post-thrombotic syndrome and thrombosis at insertion site is present in the absence of anticoagulation [16]. Catheter directed thrombolysis or thrombectomy are indicated for massive iliofemoral clot burden and/or phlegmasia cerulea dolens.

Monitoring patients post DVT is a good practice, looking for signs of bleeding or symptoms of progression of DVT with possible embolization, most patient after acute DVT are advised for early ambulation but elastic graduated compression stockings are not indicated anymore for the prevention of post-thrombotic syndrome, however, may help with symptom control or established post-thrombotic syndrome [17]. Assessment and management of DVT in pregnancy has a slightly different approach, while a low clinical probability and negative D-Dimer can rule out DVT, a positive D-Dimer has no role in pregnancy as it can increase in second and third trimesters [18].

If clinical probability is high a compression USS is indicated, if negative a repeat scan on day 3 and day 7 is advisable, alternative imaging like USS doppler of iliac veins or magnetic resonance imaging (MRI) is indicated in high clinical probability [19]. Low molecular weight heparin (LMWH) 1 mg/Kg BD is the first line treatment of DVT in pregnancy [20].

References

1. Hirsh J, Hull RD, Raskob GE. Clinical Features and Diagnosis of Venous Thrombosis. *J Am Coll Cardiol.* 1986;8(6 Suppl B):114B-127B. [PubMed](#) | [CrossRef](#)
2. Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, et al. Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis. *N Engl J Med.* 2003;349(13):1227-35. [PubMed](#) | [CrossRef](#)
3. Browse NL, Thomas ML. Source of Non-Lethal Pulmonary Emboli. *Lancet.* 1974;1(7851):258-9. [PubMed](#) | [CrossRef](#)

4. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism. *Ann Intern Med.* 2010;152(9):578-89. [PubMed](#) | [CrossRef](#)
5. Galanaud JP, Sevestre-Pietri MA, Bosson JL, Laroche JP, Righini M, Brisot D, et al. OPTIMEV-SFMV Investigators. Comparative Study on Risk Factors and Early Outcome of Symptomatic Distal Versus Proximal Deep Vein Thrombosis: Results from the OPTIMEV Study. *Thromb Haemost.* 2009;102(3):493-500. [PubMed](#) | [CrossRef](#)
6. Kearon C. Natural History of Venous Thromboembolism. *Circulation.* 2003;107(23 Suppl 1):I22-30. [PubMed](#) | [CrossRef](#)
7. Franco L, Giustozzi M, Agnelli G, Becattini C. Anticoagulation in Patients with Isolated Distal Deep Vein Thrombosis: A Meta-Analysis. *J Thromb Haemost.* 2017;15(6):1142-1154. [PubMed](#) | [CrossRef](#)
8. Palareti G, Cosmi B, Lessiani G, Roderigo G, Guazzaloca G, Brusi C, et al. Evolution of Untreated Calf Deep-Vein Thrombosis in High Risk Symptomatic Outpatients: The Blind, Prospective CALTHRO Study. *Thromb Haemost.* 2010;104(5):1063-70. [PubMed](#) | [CrossRef](#)
9. Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. *Chest.* 2021;160(6):e545-e608. [PubMed](#) | [CrossRef](#)
10. Den Exter PL, Van Es J, Erkens PM, Van Roosmalen MJ, Van Den Hoven P, Hovens MM, et al. Impact of Delay in Clinical Presentation on the Diagnostic Management and Prognosis of Patients with Suspected Pulmonary Embolism. *Am J Respir Crit Care Med.* 2013;187(12):1369-73. [PubMed](#) | [CrossRef](#)
11. Douketis JD. Treatment of Deep Vein Thrombosis: What Factors Determine Appropriate Treatment? *Can Fam Physician.* 2005;51(2):217-23. [PubMed](#)
12. EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. *N Engl J Med.* 2010;363(26):2499-510. [PubMed](#) | [CrossRef](#)
13. Othieno R, Okpo E, Forster R. Home Versus In-Patient Treatment for Deep Vein Thrombosis. *Cochrane Database Syst Rev.* 2018;1(1):CD003076. [PubMed](#) | [CrossRef](#)
14. Kearon C. Natural History of Venous Thromboembolism. *Circulation.* 2003;107(23 Suppl 1):I22-30. [PubMed](#) | [CrossRef](#)
15. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(2 Suppl):e419S-e496S. [PubMed](#) | [CrossRef](#)
16. Streiff MB. Vena Caval Filters: A Comprehensive Review. *Blood.* 2000;95(12):3669-77. [PubMed](#) | [CrossRef](#)
17. Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, et al; SOX Trial Investigators. Compression Stockings to Prevent Post-Thrombotic Syndrome: A Randomised Placebo-Controlled Trial. *Lancet.* 2014;383(9920):880-8. [PubMed](#) | [CrossRef](#)
18. Kline JA, Williams GW, Hernandez-Nino J. D-dimer Concentrations in Normal Pregnancy: New Diagnostic Thresholds are Needed. *Clin Chem.* 2005;51(5):825-9. [PubMed](#) | [CrossRef](#)
19. Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(2 Suppl):e351S-e418S. [PubMed](#) | [CrossRef](#)
20. Treatment of Venous Thrombosis in Pregnancy and After Birth Patient Information Leaflet. RCOG. 2023.